Novolog (Pharm-Up 1966) Ltd - Laporan Laba Rugi (TTM)

Novolog (Pharm-Up 1966) Ltd
IL ˙ TASE ˙ IL0011401515
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Novolog (Pharm-Up 1966) Ltd menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 1,085 1,134 1,148 1,190 1,229 1,255 1,315 1,366 1,424 1,508 1,546 1,597 1,630 1,643 1,685 1,749 1,794 2,022 2,074 2,038
Change (%) 4.48 1.23 3.69 3.31 2.11 4.72 3.94 4.24 5.88 2.51 3.34 2.07 0.80 2.50 3.82 2.57 12.69 2.60 -1.72
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 964 1,003 1,007 1,043 1,078 1,101 1,158 1,205 1,256 1,328 1,363 1,410 1,448 1,470 1,509 1,575 1,615 1,837 1,906 1,864
Change (%) 4.01 0.43 3.53 3.43 2.07 5.20 4.04 4.29 5.74 2.59 3.49 2.64 1.53 2.69 4.38 2.48 13.76 3.77 -2.19
% of Revenue 88.85 88.45 87.75 87.61 87.71 87.68 88.07 88.16 88.20 88.08 88.15 88.28 88.78 89.43 89.59 90.08 90.00 90.85 91.89 91.45
Gross Operating Profit 121 131 141 147 151 155 157 162 168 180 183 187 183 174 175 174 179 185 168 174
Change (%) 8.21 7.38 4.85 2.45 2.39 1.37 3.15 3.87 6.97 1.90 2.21 -2.25 -5.02 0.95 -1.05 3.33 3.13 -9.02 3.57
% of Revenue 11.15 11.55 12.25 12.39 12.29 12.32 11.93 11.84 11.80 11.92 11.85 11.72 11.22 10.57 10.41 9.92 10.00 9.15 8.11 8.55
SG&A 62 64 79 81 82 84 76 80 86 102 105 110 117 123 124 122 117 115 116 118
Change (%) 3.30 23.38 3.14 0.93 1.95 -8.95 5.51 6.51 18.60 3.02 5.33 6.50 5.03 0.82 -1.83 -3.74 -2.06 0.62 2.05
% of Revenue 5.70 5.64 6.87 6.84 6.68 6.67 5.80 5.89 6.01 6.74 6.77 6.90 7.20 7.50 7.38 6.98 6.55 5.69 5.58 5.79
R&D
Change (%)
% of Revenue
OpEx 1,033 1,076 1,086 1,124 1,161 1,186 1,243 1,294 1,351 1,430 1,468 1,521 1,571 1,590 1,631 1,694 1,724 1,949 2,019 1,968
Change (%) 4.12 0.91 3.53 3.30 2.11 4.84 4.08 4.40 5.86 2.62 3.66 3.23 1.21 2.60 3.88 1.78 13.02 3.57 -2.49
% of Revenue 95.25 94.92 94.62 94.47 94.47 94.47 94.58 94.71 94.86 94.84 94.95 95.24 96.32 96.72 96.81 96.87 96.13 96.40 97.32 96.56
Operating Income 52 58 62 66 68 69 71 72 73 78 78 76 60 54 54 55 69 73 56 70
Change (%) 11.60 7.25 6.56 3.42 2.07 2.70 1.39 1.24 6.35 0.39 -2.68 -21.12 -10.00 -0.37 1.82 26.92 4.63 -23.53 26.06
% of Revenue 4.75 5.08 5.38 5.53 5.53 5.53 5.42 5.29 5.14 5.16 5.05 4.76 3.68 3.28 3.19 3.13 3.87 3.60 2.68 3.44
Interest Expense -1 -7 -8 -8 -9 -8 -9 -10 -10 -13 -13 -13 -13 -13 -16 -17 -17 -13 -10 -12
Change (%) 940.56 2.04 6.80 6.46 -1.21 10.19 6.79 3.03 22.11 3.68 -1.14 -0.14 0.28 27.14 0.94 2.10 -25.22 -23.54 29.10
% of Revenue -0.07 -0.65 -0.66 -0.68 -0.70 -0.67 -0.71 -0.73 -0.72 -0.83 -0.84 -0.80 -0.79 -0.78 -0.97 -0.94 -0.94 -0.62 -0.46 -0.61
Net Income 38 40 40 40 41 42 41 43 43 48 25 24 15 -42 -20 -18 -6 40 29 20
Change (%) 5.66 -1.36 1.93 0.83 4.18 -2.16 4.88 -0.18 9.60 -47.10 -2.69 -40.18 -387.14 -53.41 -10.37 -65.52 -753.84 -27.80 -29.69
% of Revenue 3.49 3.53 3.44 3.39 3.30 3.37 3.15 3.18 3.04 3.15 1.63 1.53 0.90 -2.56 -1.16 -1.00 -0.34 1.96 1.38 0.98

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista